Skip to content
DataLookout
Menu

SOLARNCT06880055

Shield Post-Approval Study Protocol

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words
    • Trial sites expanded: 69 → 83 locations
  2. Minor Trial sites expanded: 56 → 69 locationsv6
  3. Minor Study sites: 43 to 56v5
  4. Minor Study sites: 1 to 43v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 109 words
    • Start date changed from estimate of Sep 1, 2025 to Jul 14, 2025
    v3
  6. Minor Study description revisedv2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Performance measures of the Shield test will be assessed for the second testing interval
Timeframe: 33-42 Months Post-Enrollment

Arms and interventions

Enrolled Subjects

Subjects age 45 to 81 at average risk of CRC who meet inclusion, do not meet exclusion criteria, and who successfully enroll in the study.

Diagnostic tests: Shield Blood Test for colo-rectal cancer Screening

Sites

83 sites in 1 country